As reported previously, Reed Maurer passed away on August 30 due to complications from pneumonia. He was approaching his 84th birthday.Reed has been a driver of the international pharma community in Japan like nobody else. Arriving over fifty years ago…
REGULATORY
MHLW to Promptly Seek Expert Panel Discussion on Booster Shots: Minister
The Ministry of Health, Labor and Welfare (MHLW) will promptly seek discussions at its key advisory panel on the need for booster shots for people who have already received two doses of COVID-19 vaccines, Health Minister Norihisa Tamura said on…
To read the full story
Related Article
- Japan to Offer COVID-19 Booster Shots, Targets to Be Discussed Later
September 21, 2021
- Japan Should Arrange Boosters Immediately, Mix-and-Match Doses Too: LDP
September 10, 2021
- COVID-19 Expert Omi Urges Govt to Consider Booster Shots
September 9, 2021
REGULATORY
- GSK/Vir’s COVID-19 Drug Up for MHLW Panel Review on Sept. 27
September 22, 2021
- All 4 Contenders in LDP Leadership Race Vow to Expand COVID-19 Measures
September 21, 2021
- MHLW Panel to Discuss Whether Govt Should Investigate Safety of COVID-19 Vaccines
September 21, 2021
- Japan to Start Discussions in October on Reinstating HPV Vaccine Recommendation
September 21, 2021
- Japan to Offer COVID-19 Booster Shots, Targets to Be Discussed Later
September 21, 2021
Over two years after the rollout of the cost-effectiveness assessment (CEA) scheme in April 2019, discussions on its system reform are set to go into full swing at a key reimbursement policy council known as Chuikyo. Both payer and healthcare…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…